LLY

1,013.58

-0.49%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

NVS

150.46

+0.06%↑

LLY

1,013.58

-0.49%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

NVS

150.46

+0.06%↑

LLY

1,013.58

-0.49%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

NVS

150.46

+0.06%↑

LLY

1,013.58

-0.49%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

NVS

150.46

+0.06%↑

LLY

1,013.58

-0.49%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

NVS

150.46

+0.06%↑

Strona główna・Stock List・Johnson and Johnson

Johnson and Johnson

Open

SectorHealthcare

227.69 -1.21

Buy Sell

Overview

Share price change

24h

Current

Min

229.11

Max

231.56

Key metrics
By Trading Economics
Income	119M 5.2B
Sales	-502M 24B
P/E Sector Avg	26.526 49.701
EPS	2.7
Dividend yield	2.29
Profit margin	21.756
Employees	138,200
EBITDA	182M 6.4B

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+15.11% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	2.29% 2.39%
Next Earnings	15 lip 2026
Next Dividend date	9 cze 2026
Next Ex Dividend date	26 maj 2026

Market Stats
By TradingEconomics
Market Cap	-22B 551B
Previous open	228.9
Previous close	227.69

News Sentiment

By Acuity

25%

75%

55 / 345 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

154.93 / 155.895 Support & Resistance

Johnson and Johnson Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 kwi 2026, 13:27 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson to Acquire Atraverse Medical to Bolster Cardiac Device Portfolio

23 kwi 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

22 kwi 2026, 11:27 UTC

Earnings

Intuitive Surgical Earnings Show Big Beats Don't Always Spark Stock Rallies -- Barrons.com

14 kwi 2026, 19:38 UTC

Earnings

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 kwi 2026, 14:13 UTC

Earnings

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 kwi 2026, 12:57 UTC

Earnings

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 kwi 2026, 11:19 UTC

Earnings

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

14 kwi 2026, 10:34 UTC

Earnings

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

14 kwi 2026, 10:20 UTC

Market Talk

Earnings

J&J Sees Path to Double-Digit Growth by End of Decade -- Market Talk

14 kwi 2026, 10:20 UTC

Market Talk

Earnings

J&J's Tremfya Sales Continue to Surge -- Market Talk

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson: With MedTech, Anticipate Additional Rounds of VBP in China Throughout Year, Heavier in Second Half of Year >JNJ

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson: Expect Heavier Investment in First Half of 2026 Year >JNJ

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson: With Innovative Medicine, Expect More Pronounced Sales Impact From Newly Launched Products as 2026 Progresses>JNJ

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson Announce Planned Enterprise Business Review for Dec. 8, 2026 >JNJ

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson: Anticipate Higher EPS Growth in Second Half of Year Vs First Half >JNJ

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson: With MedTech, Expect Continued Acceleration of Newly Launched Products as Year Progresses With Normalized Seasonality >JNJ

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson: With MedTech, Surgery Transformation Sales Headwinds Expected to Increase Through Year >JNJ

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson Sees 2026 Adjusted Operational EPS $11.30-$11.50 Vs Prior View $11.28-$11.48 >JNJ

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson: Anticipate Fairly Consistent Operational Sales Growth in First and Second Half With 53rd Week Affecting Second Half >JNJ

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson: With Innovative Medicine, Anticipate Generic Competition for Opsumit (Second Half in U.S.) and Simponi (First Half in EU; Potentially Second Half in U. S.) >JNJ

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson Sees 2026 Adj. Operational Sales Growth in Range of 5.6%-6.6% Vs Prior View 5.4%-6.4% >JNJ

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson: 1Q Innovative Medicine Operational Sales Growth Driven Primarily by Darzalex, Carvykti, Erleada, Rybrevant/Lazcluze, Tremfya and Spravato >JNJ

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson Raises 2026 View To Sales $100.3B-$101.3B Vs Prior View $100B-$101B >JNJ

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson 1Q Orthopaedics Sales $2.38B >JNJ

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson: 1Q MedTech Business Growth Driven Primarily by Electrophysiology Products, Abiomed, Shockwave as Well as Trauma >JNJ

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson Sees 2026 Operational Sales of $99.7B-$100.7B Vs Prior View $99.5B-$100.5B>JNJ

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson 1Q Adj EPS $2.70 >JNJ

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson: New Treatment for Bladder Cancer Inlexzo Is Outperforming All Recent Launches Based on Unique Patients Treated in First 6 Months of Approval >JNJ

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson 1Q U.S. Sales $13.33B >JNJ

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson 1Q International Sales $10.73B >JNJ

Peer Comparison

Price change

Johnson and Johnson Forecast

Price Target

By TipRanks

15.11% upside

12 Months Forecast

Average 264.75 USD 15.11%

High 285 USD

Low 240 USD

Based on 18 Wall Street analysts offering 12 month price targets forJohnson and Johnson - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

18 ratings

Buy

Hold

Sell

Based on 18 analysts giving stock ratings to Johnson and Johnson - Dist in the past 3 months.

Technical Score

By Trading Central

154.93 / 155.895Support & Resistance

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

55 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.